Annovis Bio (ANVS) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free ANVS Stock Alerts $8.31 +0.28 (+3.49%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 5:29 PM | marketbeat.comAnnovis Bio, Inc. (NYSE:ANVS) Short Interest Up 11.0% in AprilAnnovis Bio, Inc. (NYSE:ANVS - Get Free Report) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 1,610,000 shares, a growth of 11.0% from the April 15th total of 1,450,000 shares. Based on an average daily volume of 447,100 shares, the days-to-cover ratio is currently 3.6 days.May 17 at 11:00 AM | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 16, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 16, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsMay 16, 2024 | americanbankingnews.comFY2024 EPS Estimates for Annovis Bio, Inc. (NYSE:ANVS) Increased by AnalystMay 15, 2024 | benzinga.comBehind the Scenes of Annovis Bio's Latest Options TrendsMay 15, 2024 | markets.businessinsider.comBuy Rating Maintained for Annovis Bio Ahead of Key Parkinson’s Drug Trial ResultsMay 15, 2024 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for Annovis Bio, Inc. (NYSE:ANVS)Annovis Bio, Inc. (NYSE:ANVS - Free Report) - HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Annovis Bio in a research note issued on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.96) for thMay 15, 2024 | americanbankingnews.comHC Wainwright Trims Annovis Bio (NYSE:ANVS) Target Price to $23.00May 13, 2024 | finanznachrichten.deAnnovis Bio Inc.: Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial ResultsMay 13, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson’s TreatmentMay 13, 2024 | investorplace.comANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024May 13, 2024 | marketbeat.comAnnovis Bio (NYSE:ANVS) PT Lowered to $23.00 at HC WainwrightHC Wainwright cut their target price on shares of Annovis Bio from $30.00 to $23.00 and set a "buy" rating on the stock in a report on Monday.May 13, 2024 | globenewswire.comAnnovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | msn.comAnnovis Bio to post late-stage data for Parkinson's drug in JuneMay 9, 2024 | finanznachrichten.deAnnovis Bio Inc.: Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's DiseaseMay 9, 2024 | globenewswire.comAnnovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's DiseaseMay 2, 2024 | seekingalpha.comImpact Of Buntanetap Trial Results On Annovis Bio Stock And Future ProspectsMay 2, 2024 | seekingalpha.comAnnovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into QuestionApril 30, 2024 | marketbeat.comAnnovis Bio (NYSE:ANVS) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Annovis Bio in a report on Tuesday.April 30, 2024 | seekingalpha.comAnnovis Bio: Searching For Efficacy In Alzheimer's DiseaseApril 30, 2024 | marketbeat.comAnnovis Bio (NYSE:ANVS) Given New $26.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group decreased their price objective on Annovis Bio from $36.00 to $26.00 and set a "buy" rating on the stock in a research note on Tuesday.April 29, 2024 | finanznachrichten.deAnnovis Bio Inc.: Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's DiseaseApril 29, 2024 | msn.comS&P 500 Edges Higher; ON Semiconductor Earnings Top ViewsApril 29, 2024 | marketwatch.comAnnovis Bio Shares Sink After Buntanetap Study Misses EndpointApril 29, 2024 | bizjournals.comAnnovis Bio stock price plummets following mixed results for experimental Alzheimer's treatmentApril 29, 2024 | msn.comWhy Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?April 29, 2024 | msn.comAnnovis Bio tumbles 53% on data for Alzheimer's candidate buntanetapApril 29, 2024 | finance.yahoo.comUPDATE 2-Annovis tumbles as Alzheimer's treatment misses in mid-stage studyApril 29, 2024 | finance.yahoo.comAnnovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 StudyApril 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 12:04 PM with a stated reason of "LULD pause." Trading set to resume at 12:04 PM. April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause." Trading set to resume at 11:04 AM. April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 11:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause." Trading set to resume at 10:04 AM. April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause." Trading set to resume at 10:04 AM. April 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | reuters.comAnnovis Bio reports positive results in mid-stage Alzheimer's treatment trialApril 29, 2024 | globenewswire.comAnnovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's DiseaseApril 29, 2024 | marketbeat.comTrading was temporarily halted for "ANVS" at 09:04 AM with a stated reason of "News pending."April 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Up as Depression Drug Meets Study GoalsApril 16, 2024 | marketbeat.comTraders Buy High Volume of Call Options on Annovis Bio (NYSE:ANVS)Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 3,923 call options on the stock. This represents an increase of approximately 118% compared to the typical volume of 1,803 call options.April 4, 2024 | msn.comAnnovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical TrialsApril 4, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Annovis Bio, Inc. Issued By Brookline Capital Management (NYSE:ANVS)Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Analysts at Brookline Capital Management boosted their Q1 2024 earnings per share estimates for shares of Annovis Bio in a research report issued to clients and investors on Monday, April 1st. Brookline Capital Management analyst T. Bussian now expect Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. ANVS Media Mentions By Week ANVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼0.590.42▲Average Medical News Sentiment ANVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼193▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Immix Biopharma News Today Reneo Pharmaceuticals News Today Celularity News Today CalciMedica News Today AEON Biopharma News Today Checkpoint Therapeutics News Today Eledon Pharmaceuticals News Today Kezar Life Sciences News Today Eagle Pharmaceuticals News Today BioLineRx News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressUrgent Nvidia WarningAltimetry"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
